Cellerant Therapeutics, Inc. today announced it has been awarded a two-year, $800,000 Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Disease (NIAID) at the National Institutes of Health (NIH) for the project titled, “Expansion of Human Hematopoietic Stem Cells for Rescue in Biodefense Applications.” This is Cellerant’s second NIH grant related to the use of adult hematopoietic (blood-forming) stem and progenitor cells for the rescue of individuals exposed to lethal doses of radiation.
